#USA #New York #Class Action #Soleno Therapeutics #Faruqi and Faruqi

Important Investor Update on Soleno Therapeutics

Faruqi & Faruqi, LLP, a renowned national securities law firm, is reaching out to investors of Soleno Therapeutics, Inc. to alert them about the imminent deadline for filing a federal securities class action. The deadline is set for May 5, 2026, making it critical for affected investors to take action soon.

Background of the Case

Soleno Therapeutics (NASDAQ: SLNO) is currently facing scrutiny regarding its Phase 3 clinical trial for its drug candidate, DCCR, designed to treat hyperphagia in patients with Prader-Willi syndrome (PWS). Allegations assert that the company, along with its executives, has failed to disclose significant safety issues related to DCCR during clinical trials. These claims suggest that the company misrepresented the safety and efficacy of DCCR, which could have serious ramifications for investors.

Reports from credible sources, including a critical publication from Scorpion Capital LLC, have raised alarms about the integrity of Soleno’s clinical data and have pointed to potential risks related to the drug’s administration. This negative exposure has reportedly caused a notable decline in Soleno’s stock price, triggering concerns from the investor community.

Investor Rights and Options

Investors who purchased shares between March 26, 2025, and November 4, 2025, are encouraged to explore their rights and options. Faruqi & Faruqi stands ready to assist those who may have suffered financial losses due to this situation. Josh Wilson, a Senior Partner at the firm, invites affected investors to get in touch directly for a confidential discussion on their legal rights and possible actions. Interested investors can reach him at 877-247-4292 or 212-983-9330 (Ext. 1310).

Implications of Missed Deadlines

Failing to act before the deadline could mean missing out on potential recovery avenues in the class action suit against Soleno. The role of the lead plaintiff is crucial—it is assigned to the investor who stands to gain the most financially from the lawsuit, and who is willing to take a stand on behalf of the class. It's essential to understand that participating as a lead plaintiff might optimize your chances of recovery, but it is not mandatory. Investors can also opt to remain as absent class members while retaining their rights to recover any potential damages.

Importance of Informed Decisions

The ongoing investigation by Faruqi & Faruqi emphasizes the importance of staying informed and making educated decisions, especially in volatile situations like this one. The potential consequences of the allegations leveled against Soleno Therapeutics are significant, affecting not just the company’s financial outlook but also the safety of its products.

The firm has a rich history of securing millions for investors since its inception in 1995, and is committed to uphold transparency and advocate vigorously for its clients. Investors with any additional information or past experiences related to Soleno’s operational conduct—whistleblowers, former employees, and shareholders—are also encouraged to step forward and contribute to the ongoing inquiry.

To stay updated on this developing story, interested parties can follow updates via LinkedIn, X, or Facebook. Further insights regarding the ongoing class action can be found at www.faruqilaw.com/SLNO.

In summary, as the deadline approaches, investors are urged to act swiftly and seek legal advice if they believe they have been impacted by the alleged conduct of Soleno Therapeutics. Their potential recovery might hinge on timely action and informed choices made in the upcoming weeks.